Effect of cerivastatin on peripheral capillary permeability to albumin and peripheral nerve function in diabetic rats

被引:8
作者
Cohen-Boulakia, F. E.
Tarhzaoui, K.
Valensi, P. E.
Lestrade, R. A.
Albertini, J. P.
Behar, A.
机构
[1] Univ Paris 13, Lab Nutr Metab Dis & Cardiovasc Prevent, Hop Jean Verdier, APHP,CRNH,IDF, F-93000 Bobigny, France
[2] Univ Paris 06, Biophys Lab, Paris, France
关键词
capillary filtration of albumin; lymphatic dysfunction; nerve function; diabetes; statins; VASCULAR-PERMEABILITY; STATINS; SIMVASTATIN; ROSUVASTATIN; REPERFUSION; FILTRATION; INJURY; RISK;
D O I
10.1016/j.diabet.2006.11.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. - To examine the effect of cerivastatin on capillary permeability to albumin and peripheral nerve function in diabetic rats. Animals. - Diabetes was induced in male Wistar rats by i.p. injection of streptozotocin (STZ) at the age of 5 days. Forty diabetic rats were randomized in two groups: one treated by cerivastatin (diabetic treated group, DT) and the other untreated (diabetic untreated group, DU). The data were compared to a group of normal rats. Measurements. - The peripheral capillary filtration of albumin (CFA) was studied on a limb by a non-invasive isotopic method, and nerve electrophysiological measurements were performed. Rats were followed-up until 6 months. In group DU albumin retention (AR) increased by 3 months and lymphatic uptake of interstitial albumin was impaired at 6 months. None of these disorders was observed in group DT. Motor and sensory nerve conduction velocities (MNCV and SNCV) were significantly slower at 6 months in group DU but not in group DT as compared to control rats. The duration of the sensory nerve action potential (SNAP) was significantly longer in group DU than in control rats at 6 months whereas it did not differ in group DT and in control animals. Conclusions. - This study shows that cerivastatin may prevent the peripheral increase in CFA and lymphatic dysfunction induced by diabetes. These beneficial effects on microcirculation may be involved in the prevention of nerve function deterioration. The underlying mechanisms are likely to be independent of a lipid-lowering effect, but their clarification needs further investigations. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 36 条
  • [1] Prolonged ischemic conduction failure after reperfusion in diabetic nerve
    Baba, M
    Nukada, H
    McMorran, D
    Takahashi, K
    Wada, R
    Yagihashi, S
    [J]. MUSCLE & NERVE, 2006, 33 (03) : 350 - 355
  • [2] Preclinical and clinical pharmacology of cerivastatin
    Bischoff, H
    Heller, AH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B) : 18J - 25J
  • [3] Buchthal F., 1966, Brain Res, V3, P1, DOI [10.1016/0006-8993(66)90056-4, DOI 10.1016/0006-8993(66)90056-4]
  • [4] Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models
    Cameron, N
    Cotter, M
    Inkster, M
    Nangle, M
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 : S35 - S39
  • [5] In vivo sequential study of skeletal muscle capillary permeability in diabetic rats: Effect of anthocyanosides
    Cohen-Boulakia, F
    Valensi, PE
    Boulahdour, H
    Lestrade, R
    Dufour-Lamartinie, JF
    Hort-Legrand, C
    Behar, A
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (07): : 880 - 885
  • [6] COHENBOULAKIA F, 1993, EUR J LYMPHOL, V4, P75
  • [7] In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products
    Diomede, L
    Albani, D
    Sottocorno, M
    Donati, MB
    Bianchi, M
    Fruscella, P
    Salmona, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (08) : 1327 - 1332
  • [8] Statins and risk of polyneuropathy -: A case-control study
    Gaist, D
    Jeppesen, U
    Andersen, M
    Rodríguez, LAG
    Hallas, J
    Sindrup, SH
    [J]. NEUROLOGY, 2002, 58 (09) : 1333 - 1337
  • [9] Gazarin S, 2002, J NEPHROL, V15, P690
  • [10] Statins and peripheral neuropathy
    Jeppesen, U
    Gaist, D
    Smith, T
    Sindrup, SH
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 54 (11) : 835 - 838